Table 2 Molecular-targeted therapies in clinical trials

Jul 13, 2014

10 likes | 132 Views

Table 2 Molecular-targeted therapies in clinical trials. Tanaka, S. et al . ( 2012) Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end? Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2012.204.

Share Presentation

Embed Code

Link

therapeutic avenues
diagnostic
et al
dead end
clinical trials

carl

Download Presentation

Table 2 Molecular-targeted therapies in clinical trials

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

Table 2Molecular-targeted therapies in clinical trials Tanaka, S. et al. (2012) Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end? Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2012.204

Targeted Therapies in Hematology Oncology

918 views • 61 slides

Emerging Antiplatelet Therapies and the Latest Clinical Trials

Ongoing Trials Evaluating Novel Antiplatelet Drugs or Strategies in ACS and PCI. CURRENT (dosing)TRITON (new ADP)PLATO (new ADP)CHAMPION (IV ADP)ERASE (IV to po ADP)EARLY ACS (IIb/IIIa timing)TRACER and 2P (TRA). Study Design. Clopidogrel High-Dose GroupClopidogrel 600 mg loading dose Day 1 f

315 views • 14 slides

Clinical Trials

Clinical Trials. Jean Bourbeau, MD Respiratory Epidemiology and Clinical Research Unit McGill University Clinical Epidemiology (679) June 17, 2005. Clinical Trial Objectives. Define an experimental study and distinguish the major types

2.39k views • 75 slides

Clinical Trials Budgeting, Part 2

Agenda. Overview of clinical trials fund setup by OSP/OSPAInvoicing for study start-up feesInvoicing for per patient/milestone capitation fundsTracking patient enrollment and/or study milestonesUnderstanding study income versus study costsClosing out study funds. OSP Award Process. In order to

298 views • 19 slides

Clinical Trials

Clinical Trials. Receiving the NOGA . What is a NOGA? Notice of Grant Award – an “agreement” between the Sponsor and University of Minnesota Once the NOGA is received in SFR, the Manager passes it on to the SFR Accountant. Creating the First Invoice. When / how is the first invoice created?

288 views • 12 slides

Table 3 Immunotherapy in clinical trials for glioblastoma

Table 3 Immunotherapy in clinical trials for glioblastoma. Tanaka, S. et al . ( 2012) Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end? Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2012.204.

274 views • 1 slides

Targeted Cancer Therapies

Targeted Cancer Therapies. How they work and the future of medicine. Every cell has a set lifespan After that lifespan has been reached, a cell undergoes apoptosis (programmed cell death). The life(span) of a cell. How does apoptosis work?. The Apoptotic Molecules.

510 views • 24 slides

Endocrine resistance: molecular pathways and rational development of targeted therapies

Endocrine resistance: molecular pathways and rational development of targeted therapies Grazia Arpino Università di Napoli Federico II. Enhancing Endocrine Therapy for Breast Cancer. Current Endocrine Therapy : Tamoxifen ; aromatase inhibitors

1.08k views • 66 slides

Topics in Clinical Trials (2 ) - 2012

Topics in Clinical Trials (2 ) - 2012. J. Jack Lee, Ph.D. Department of Biostatistics University of Texas M. D. Anderson Cancer Center. 1: Study Population. Definition of study population What is population of interest? Generalization, inference making

501 views • 39 slides

Table 3 VEGF pathway‑targeted drugs currently in neoadjuvant clinical trials

Table 3 VEGF pathway‑targeted drugs currently in neoadjuvant clinical trials. Ebos, J. M. L. & Kerbel, R. S. (2011) Antiangiogenic therapy: impact on invasion, disease progression, and metastasis Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2011.21.

154 views • 1 slides

Clinical Trials Budgeting, Part 2

Clinical Trials Budgeting, Part 2. Agenda. Overview of clinical trials fund setup by OSP/OSPA Invoicing for study start-up fees Invoicing for per patient/milestone capitation funds Tracking patient enrollment and/or study milestones Understanding study income versus study costs

344 views • 19 slides

Using Non-targeted Therapies in Targeted Lung Cancer Populations

Using Non-targeted Therapies in Targeted Lung Cancer Populations. Nathan Pennell, M.D., Ph.D. September 6, 2014. Objectives. Discuss the role of chemotherapy in molecularly defined populations Discuss the addition of chemo and/or bevacizumab (Avastin) to targeted therapy

647 views • 42 slides

The near future: molecular targeted therapies for metastatic prostate cancer

NEW PERSPECTIVES IN METASTATIC PROSTATE CANCER Rome, June 15, 2012 CINBO. The near future: molecular targeted therapies for metastatic prostate cancer. Mediterranean School of Oncology. Alessandra Felici, Oncologia Medica A Istituto Regina Elena Rome. The Two-Compartment Model.

840 views • 44 slides

Clinical Trials

Clinical Trials. The Way We Make Progress Against Disease. What Are Clinical Trials?. Research studies involving people Try to answer scientific questions and find better ways to prevent, diagnose, or treat disease. Why Is Participation in Clinical Trials Important?.

812 views • 31 slides

Table 1 Clinical trials of add-on therapies to RAS blockade in DKD

Table 1 Clinical trials of add-on therapies to RAS blockade in DKD. Fernandez-Fernandez, B. et al. (2014) Therapeutic approaches to diabetic nephropathy—beyond the RAS Nat. Rev. Nephrol. doi:10.1038/nrneph.2014.74.

70 views • 1 slides

Table 1 Timing of clinical trials and FDA approval for selected targeted therapies

Table 1 Timing of clinical trials and FDA approval for selected targeted therapies. Maxwell, K. N. & Domchek, S. M. ( 2012) Cancer treatment according to BRCA1 and BRCA2 mutations Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2012.123.

170 views • 1 slides

Table 2 Ongoing clinical trials of active amyloid‑β immunotherapies

Table 2 Ongoing clinical trials of active amyloid‑β immunotherapies. Lemere, C. A. & Masliah, E. (2010) Can Alzheimer disease be prevented by amyloid‑β immunotherapy? Nat. Rev. Neurol. doi:10.1038/nrneurol.2009.219.

110 views • 1 slides

Table 1 Clinical trials on AAV

Table 1 Clinical trials on AAV. Chen, M. & Kallenberg, C. G. M. (2010) ANCA-associated vasculitides—advances in pathogenesis and treatment Nat. Rev. Rheumatol. doi:10.1038/nrrheum.2010.158.

136 views • 1 slides

Targeted Therapies in Lung Cancer

Targeted Therapies in Lung Cancer. Martin J.Edelman, MD University of Maryland. Thoracic Oncology: Not Feeling Guilty Any More. Established first, second and third line therapies based upon solid evidence. Increasing cure rates in stage III disease.

833 views • 40 slides

Table 2 Randomized ICH clinical trials 2000–2010

Table 2 Randomized ICH clinical trials 2000–2010. Adeoye, O. & Broderick, J. P. (2010) Advances in the management of intracerebral hemorrhage Nat. Rev. Neurol. doi:10.1038/nrneurol.2010.146.

116 views • 1 slides

The near future: molecular targeted therapies for metastatic prostate cancer

460 views • 44 slides

Clinical Trials

ClinConnect is a comprehensive online platform designed to streamline and optimize the process of conducting clinical trials. It serves as a centralized hub connecting researchers, healthcare professionals, sponsors, and participants, facilitating efficient collaboration and data management throughout the trial lifecycle. Visit: https://clinconnect.io/

59 views • 5 slides

More Related